Starmer must make a deal to avoid Trump’s pharma tariffs or risk a major hit to the NHS and the UK’s leading pharmaceutical industry, write Ben Ramanauskas and Sean Phillips

Last week, President Trump warned of “a major tariff”: up to 25 per cent on pharmaceutical products entering the United States. Currently, there is an exemption for pharmaceuticals on the baseline 10 per cent tariffs for goods coming into the US, but the President said that will change “very shortly”.

Were such tariffs to materialise, the impact on one of the UK’s most successful industries – key to the government’s plans to boost growth – will be hugely significant, increasing costs for the NHS and with the potential for significant disruption to the development and supply of medicines, both for patients in the UK and around the world.

What would tariffs mean for UK pharma?

Pharmaceuticals are one of the UK’s most successful industries, supporting hundreds of thousands of high quality jobs, with the sector’s........

© City A.M.